BPC September 27 update

17 Phase 3 biotech stock catalysts slated for 4Q 2019

Weekly watchlist

With just one trading day left in the third quarter, eyes now turn toward the final quarter of 2019, which promises to be full of price-moving catalysts. This week we highlight Phase 3 data readouts slated for the final quarter, which will be followed over the next two weeks by Phase 1/2 readouts to watch and regulatory (PDUFA/Advisory Committee) dates.

First, let’s review the week that was.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced Monday that the FDA has agreed to lowering the enrolment in a Phase 3 trial of once-nightly sodium oxybate, FT218, in the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. Enrolment is now expected to be completed by the end of 2019, compared with recent guidance of 2H 2020. Top-line data are due in 2Q 2020. Shares closed the week up 26% to $4.25.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced Wednesday data from its Phase 2a trial of EDP-305 for the treatment of non-alcoholic steatohepatitis (NASH). The trial only just met the primary endpoint (p=0.049) and the high-dose cohort saw 51% of patients exhibiting pruritus (itching of the skin). Shares closed the week down 16% to $60.28.

The Medicines Company (NASDAQ: MDCO) announced that it met primary and secondary endpoints in both its Phase 3 ORION-9 trial of inclisiran in patients with Heterozygous Familial Hypercholesterolemia (HeFH) and its ORION-10 trial in patients with atherosclerotic cardiovascular disease (ASCVD).

AzurRx BioPharma Inc (NASDAQ: AZRX) shares closed the week down 42% to $0.58 following negative data from its Phase 2 clinical trial of MS1819 for the treatment of exocrine pancreatic insufficiency in cystic fibrosis (CF).

Akcea Therapeutics, Inc. (NASDAQ: AKCA) shares closed Monday down 20% to $18.04 on news of the departures of Paula Soteropoulos, chief executive officer, Sarah Boyce, president, and Jeff Goldberg, chief operating officer.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) shares closed Friday down 37% to $6.25 following news from its partner, Avanir Pharmaceuticals, that its Phase 3 trial of AVP-786 for the treatment of moderate-to-severe agitation in patients with Alzheimer’s dementia did not meet its primary and key secondary endpoints.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) shares closed Thursday up 23% to $1.69 on news that its open-label, dose-finding Phase 2 trial evaluating intravenous (IV) ganaxolone in patients with refractory status epilepticus (RSE), met the primary endpoint. Shares pulled back Friday to close the week at $1.52.

---

15 Phase 3 biotech stocks catalysts slated for 4Q 2019:

Drug Stage Catalyst Market Cap

ACST – Acasti Pharma Inc.
CaPre (TRILOGY 1 and 2)
Hypertriglyceridemia

Phase 3 Phase 3 top-line data due in December 2019 (1) and January 2020 (2).
$183.2 million

ALNA – Allena Pharmaceuticals Inc.
Reloxaliase ALLN-177 (URIROX-1)
Enteric Hyperoxaluria

Phase 3 Phase 3 top-line data due 4Q 2019.
$105.6 million

APLS – Apellis Pharmaceuticals Inc.
APL-2 subcutaneous PEGASUS
Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 3 Phase 3 data due December 2019.
$1.7 billion

AUPH – Aurinia Pharmaceuticals Inc
Voclosporin - AURORA
Lupus

Phase 3 Phase 3 data due 4Q 2019.
$428.7 million

AXSM – Axsome Therapeutics Inc.
AXS-05 STRIDE-1
Treatment resistant depression

Phase 3 Phase 3 data due 4Q 2019.
$710.1 million

BGNE – BeiGene Ltd.
Zanubrutinib (BGB-3111) - ASPEN
Waldenström’s macroglobulinemia

Phase 3 Phase 3 top-line data due 2H 2019.
$7.5 billion

BMRN – BioMarin Pharmaceutical Inc.
Vosoritide
Achondroplasia

Phase 3 Phase 3 top-line data due end of 2019.
$12.3 billion

CARA – Cara Therapeutics Inc.
KORSUVA (CR845/difelikefalin) oral
Stage 3-4 Chronic Kidney Disease-Associated Pruritus

Phase 2 Phase 2 data due 4Q 2019.
$902.9 million

HALO – Halozyme Therapeutics Inc.
HALO-301
Pancreatic cancer

Phase 3 Phase 3 data due by December 2019.
$2.3 billion

INCY – Incyte Corporation
Itacitinib - GRAVITAS-301
Treatment-naïve acute GVHD

Phase 3 Phase 3 data due 2H 2019.
$16.9 billion

KALA – Kala Pharmaceuticals Inc.
KPI‑121 0.25% STRIDE 3
Dry eye disease

Phase 3 Phase 3 data due 4Q 2019.
$118.7 million

KPTI – Karyopharm Therapeutics Inc.
Selinexor - BOSTON
Multiple myeloma

Phase 3 Phase 3 data due end of 2019 or into 2020.
$647.1 million

OPK – Opko Health Inc.
hGH-CTP
Children - growth hormone deficiency

Phase 3 Phase 3 data due 4Q 2019.
$1.3 billion

RETA – Reata Pharmaceuticals Inc.
Bardoxolone methyl - CARDINAL
Chronic Kidney Disease Caused by Alport Syndrome

Phase 2/3 Phase 3 data due 2H 2019.
$4.8 billion

SAGE – Sage Therapeutics Inc.
SAGE-217 - MOUNTAIN
Major Depressive Disorder (MDD)

Phase 3 Phase 3 data due 4Q 2019 or 1Q 2020.
$7.5 billion

SLGL – Sol-Gel Technologies Ltd.
TWIN
Acne

Phase 3 Phase 3 data due 4Q 2019.
$158.8 million

SUPN – Supernus Pharmaceuticals Inc.
SPN-810
Impulsive Aggression in ADHD

Phase 3 Phase 3 data due 4Q 2019.
$1.4 billion